The Abilify compulsive gambling class action represents one of the largest pharmaceutical litigation settlements in recent years, involving thousands of patients who developed pathological gambling, compulsive eating, shopping, and hypersexual urges while taking this antipsychotic medication. The lawsuits stem from regulatory failures by the manufacturer to adequately warn patients and prescribers about these serious behavioral side effects—despite evidence that the FDA documented approximately 200 cases of compulsive behaviors linked to the drug before issuing formal warnings in May 2016. This class action has already resulted in settlements exceeding $1.2 billion globally, with individual payouts ranging from $20,000 to over $500,000 depending on the severity of documented harm. A concrete example illustrates the severity of injuries at stake: Christina Milisic, a Canadian plaintiff, lost more than $400,000 to compulsive gambling while taking Abilify.
Her case exemplifies how these side effects can devastate patients’ financial security and personal lives. Many plaintiffs in the class action had no prior history of gambling problems or compulsive behaviors before starting Abilify, and the urges typically subsided after discontinuing the medication—a pattern that strengthened claims that the drug itself was directly responsible for the harm. The litigation spans both U.S. federal courts and Canadian provincial class actions, with major settlements approved for Ontario and Quebec in early 2025. Patients who took Abilify or Abilify Maintena before the FDA’s warning in May 2016—and who developed gambling problems or other compulsive behaviors as a result—may still be eligible to file claims and receive compensation.
Table of Contents
- What Triggered the FDA Warning and Class Action Litigation?
- Understanding the Compulsive Behaviors Associated with Abilify
- The Global Settlement Structure and Compensation Amounts
- How to File a Claim in the Abilify Class Action
- Documentation Requirements and Common Barriers to Approval
- The Canadian Class Action and Its Specific Terms
- Ongoing Litigation and the Future of Abilify Claims
- Conclusion
What Triggered the FDA Warning and Class Action Litigation?
The Abilify compulsive gambling problem emerged slowly through post-market surveillance, with regulatory agencies first becoming aware of the issue years before a formal warning was issued. In November 2015, Health Canada ordered labelling changes to Abilify and Abilify Maintena to advise of the increased risk of pathological gambling and hypersexuality. Six months later, on May 3, 2016, the U.S. FDA announced that warnings regarding “compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex” would be added to Abilify’s label. At the time of the FDA warning, the agency had already documented approximately 200 adverse event reports linking the drug to these compulsive behaviors—a significant number of documented cases that should have prompted an earlier warning to the public.
The delay in issuing these warnings became central to the litigation strategy. Patients and their attorneys argued that Bristol-Myers Squibb, the drug’s manufacturer, delayed communicating known risks to doctors and patients. In a related but separate enforcement action, the U.S. Justice Department settled with Bristol-Myers Squibb for $19.5 million in december 2016, specifically over unlawful marketing practices related to Abilify. This settlement indicated that the company’s promotional activities may have minimized or obscured serious side effects, preventing physicians from making fully informed prescribing decisions.
Understanding the Compulsive Behaviors Associated with Abilify
Abilify was prescribed to patients for a range of psychiatric conditions, including bipolar disorder, major depression (as an add-on therapy), schizophrenia, and autism spectrum disorder. However, the compulsive behavioral side effects that emerged were distinct from the conditions the drug was meant to treat. Patients reported experiencing intense, almost irresistible urges to gamble—some describing the urge as feeling “foreign” or contrary to their normal personality and habits. The compulsive gambling wasn’t limited to mild or occasional betting; many affected patients experienced severe gambling binges that resulted in financial ruin, debt accumulation, and damaged relationships.
Beyond gambling, documented compulsive behaviors included pathological shopping, hypersexuality, binge eating, and other reward-seeking behaviors. A critical limitation of the Abilify case is that not all patients taking the drug develop these side effects—the behaviors appear to emerge in a subset of patients, making it difficult to predict who will be affected. However, once the behaviors develop, they typically persist and intensify if the patient continues taking the medication, and they usually resolve after discontinuation. This pattern distinguishes Abilify-related compulsive behaviors from the natural compulsive urges someone might develop due to other causes, which strengthens causation arguments in litigation.
The Global Settlement Structure and Compensation Amounts
The global Abilify settlement has been structured across multiple jurisdictions and reached settlement agreements totaling more than $1.2 billion. In the United States, Bristol-Myers Squibb agreed to a settlement of $534 million to resolve thousands of pending product liability lawsuits. Bellwether trials conducted in 2024—these are representative cases selected to gauge how juries might view similar claims—resulted in individual awards ranging from $20,000 to over $500,000, depending on factors such as the duration of medication use, the severity of the gambling losses or compulsive behavior, the quality of medical documentation, and the plaintiff’s ability to prove causation.
In Canada, the scope of compensation is being addressed through separate class action settlements. The CAD $14.75 million settlement approved for Ontario and Quebec class members will be distributed among approved claimants who meet the class definition: Canadian residents who were prescribed Abilify or Abilify Maintena before February 23, 2017, and who developed pathological gambling, compulsive eating, shopping, or hypersexuality as a result. The amount per claimant in the Canadian settlement will depend on the total number of valid claims submitted and the severity tier assigned to each claim—more severe cases with greater financial losses typically receive higher payouts than minor cases.
How to File a Claim in the Abilify Class Action
The claims filing process varies depending on jurisdiction. For the Canadian settlement, a 240-day claims period began after the Notice of Settlement Approval was published in late March or early April 2025. During this window, eligible class members must submit a claim form along with supporting documentation. For U.S. claimants, the process is overseen by claims administrators for the various state-level and federal settlements.
Claimants must provide proof that they took Abilify or Abilify Maintena, documentation of the compulsive behavior they developed, medical records showing the temporal relationship between medication use and symptom onset, and evidence of financial or personal damages resulting from the compulsive behavior. The most important practical consideration is documenting the causation link between the drug and the behavior. Unlike other personal injury claims, Abilify compulsive gambling claims require more than just a diagnosis; they require proof that you did not have a history of compulsive gambling or similar behaviors before starting the medication, that the behaviors emerged shortly after beginning Abilify, and that the behaviors resolved or significantly improved after stopping the drug. Medical records, psychiatric evaluations, banking statements showing unusual spending patterns or gambling transactions, and testimony from family members can all strengthen a claim. If you took Abilify and developed compulsive behaviors, it is advisable to consult with a class action attorney or review the claims administrator’s website to understand eligibility and deadline requirements specific to your jurisdiction.
Documentation Requirements and Common Barriers to Approval
A significant limitation in many Abilify claims is the quality of medical documentation available. Some patients were not formally diagnosed with pathological gambling or compulsive behaviors at the time they experienced them; they may have simply gambled away money without disclosing the extent of their behavior to their physician. Without contemporaneous medical records documenting the compulsive behavior and its timing relative to Abilify use, the claims administrator may require additional evidence—such as affidavits from family members, financial records, or even expert testimony—to establish causation. This can complicate the claims process and may result in some claims being denied or reduced if documentation is insufficient.
Another barrier is the requirement to prove that you did not have pre-existing compulsive gambling or shopping behaviors before taking Abilify. If you have any history of gambling or shopping problems—even minor ones—the claims administrator may argue that Abilify did not cause your current behavior, but rather exacerbated a pre-existing condition. Some settlements provide lower payouts for claimants with partial pre-existing histories, while others may deny claims altogether. Additionally, if your only evidence of harm is gambling losses, but you cannot prove that a physician’s failure to warn you about the risk prevented you from making a different medication choice, some jurisdictions may reduce compensation. It’s critical to gather as much medical documentation and corroborating evidence as possible before filing.
The Canadian Class Action and Its Specific Terms
The Canadian Abilify class action settlement has distinct features that apply to residents of Ontario and Quebec. The class definition includes individuals who were prescribed Abilify or Abilify Maintena at any time before February 23, 2017, and who developed pathological gambling, compulsive eating, shopping, or hypersexuality while on the medication. The cutoff date of February 23, 2017, corresponds to when enhanced labeling warnings became fully effective in Canada; the assumption is that prescriptions issued after that date would have included adequate warnings, reducing the manufacturer’s liability for patients who started treatment after that point. The CAD $14.75 million fund is significantly smaller than the global U.S.
settlements, which reflects both the smaller Canadian population and the fact that many Canadian residents pursued claims through U.S. courts as well. For Canadian claimants, the key step is to identify which settlement administrator is handling claims in your province and submit your claim form with supporting documentation before the 240-day deadline expires. If you live outside Ontario and Quebec but are otherwise eligible, you may still be able to pursue a claim through the U.S. federal litigation or state-specific settlements depending on where you live or where you received treatment.
Ongoing Litigation and the Future of Abilify Claims
As of early 2025, not all Abilify litigation has been fully resolved. Federal cases in the United States remain centralized under MDL 2734 (Abilify Products Liability Litigation) in the Northern District of Florida, where bellwether trials are continuing to test additional claims and refine damages estimates. Some individual defendants and settlement agreements are still being negotiated, and new claims continue to be filed in some jurisdictions.
This ongoing activity suggests that settlement amounts may continue to increase and that additional compensation opportunities may emerge for previously excluded claimants or those with exceptional harm. The long-term trajectory of Abilify litigation reflects a broader shift in pharmaceutical regulation and litigation strategy: manufacturers are increasingly held accountable not just for failing to warn of known risks, but for delaying the dissemination of safety information that regulatory agencies have already identified. Future cases involving psychiatric medications and behavioral side effects will likely reference the Abilify litigation as a precedent, putting pressure on manufacturers to disclose emerging safety signals more rapidly and more completely to physicians and patients.
Conclusion
The Abilify compulsive gambling class action represents a landmark settlement for patients who developed pathological gambling, compulsive eating, shopping, and hypersexual urges while taking this antipsychotic medication. With settlements exceeding $1.2 billion globally and individual awards ranging from $20,000 to $500,000, the litigation has validated that many patients were harmed by inadequate warnings and delayed regulatory action. Eligibility and compensation depend on documented proof of medication use, the emergence of compulsive behaviors during treatment, and the absence of pre-existing compulsive tendencies—making thorough documentation critical.
If you took Abilify before the FDA warning in May 2016 and subsequently developed compulsive gambling or related behaviors, you may still be eligible to file a claim. The Canadian settlement offers a 240-day claims period that began in spring 2025, while U.S. claimants can pursue compensation through multiple state and federal settlements. Contact a class action attorney or visit the settlement administrator’s website for your jurisdiction to confirm eligibility, gather required documentation, and submit your claim before any deadlines expire.